Business · 10/11/20261 min read
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
Summary
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization…
Original source language: GlobeNewswire — Mergers and AcquisitionsOpen original release →